EUVIMEDEUVIMED entdecken
Multizentrische Studie

Next-generation sequencing of targetable gene fusions in radioiodine-refractory thyroid cancer: a multicenter study

Jungmin Yoo iD, Mijin Kim iD, Hee Kyung Kim iD, Dong Yeob Shin iD, Min Ji Jeon iD, Bo Hyun Kim iD, Ho-Cheol Kang iD, Jaekyung Lee iD, Dong-Jun Lim iD, Won Gu Kim iD

Endocrine-Related Cancer · 2025

DOI: 10.1530/erc-25-0089 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Jungmin Yoo und 9 weiteren Autor:innen. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Iodine Radioisotopes, Gene Fusion, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We aimed to determine the prevalence and clinical significance of targetable gene fusions in patients with radioiodine-refractory thyroid cancer. This multicenter retrospective cohort study enrolled 111 patients from five tertiary medical centers, with molecular profiling performed using targeted next-generation sequencing. The analysis revealed that 58 (52.3%) patients possessed BRAFV600E mutation, while 25 (22.5%) had RAS mutations. Among the 20 (18.0%) patients with gene fusions, 13 had RET fusions, three had NTRK fusions, one had a BRAF fusion, and three had nondriver gene fusions. The group with targetable gene fusions was significantly younger compared to those with BRAF or RAS mutations (P < 0.001) and predominantly had classic papillary thyroid carcinoma. Furthermore, targetable gene fusions were detected in 30.8% of patients with refractory thyroid cancer harboring wild-type BRAF. More than half of the patients received systemic tyrosine kinase inhibitor therapy and three patients with confirmed RET or NTRK fusions achieved meaningful clinical benefit with selective agents. These findings suggest that a stepwise molecular testing strategy – initiating with BRAF single gene analysis followed by next-generation sequencing for assessing targetable gene fusions – may be a rational approach, particularly for younger patients with papillary thyroid carcinoma, for identifying candidates for precision therapy. This supports the integration of molecular profiling into routine clinical practice for radioiodine-refractory thyroid cancer and emphasizes its utility in guiding personalized treatment decisions in this challenging disease subset.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsIodine RadioisotopesGene FusionOncogene Proteins, FusionHumansFemaleMaleMiddle AgedHigh-Throughput Nucleotide SequencingAdultRetrospective StudiesAgedProto-Oncogene Proteins B-rafYoung AdultProto-Oncogene Proteins c-retMutationAged, 80 and over

Stichwörter der Autor:innen

BRAFNTRKRETgene fusionmutationnext-generation sequencingthyroid carcinoma

Substanzen

Iodine RadioisotopesProto-Oncogene Proteins B-rafBRAF protein, humanProto-Oncogene Proteins c-retRET protein, humanOncogene Proteins, Fusion

Autor:innen und Institutionen

ORCID-Profile: Jungmin Yoo, Mijin Kim, Hee Kyung Kim, Dong Yeob Shin, Min Ji Jeon, Bo Hyun Kim, Ho-Cheol Kang, Jaekyung Lee, Dong-Jun Lim, Won Gu Kim

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Yoo, J., Kim, M., Kim, H. K., Shin, D. Y., Jeon, M. J., Kim, B. H., Kang, H. C., Lee, J., Lim, D. J., & Kim, W. G. (2025). Next-generation sequencing of targetable gene fusions in radioiodine-refractory thyroid cancer: a multicenter study. Endocrine-Related Cancer. https://doi.org/10.1530/erc-25-0089

Vancouver

Yoo J, Kim M, Kim HK, Shin DY, Jeon MJ, Kim BH, et al. Next-generation sequencing of targetable gene fusions in radioiodine-refractory thyroid cancer: a multicenter study. Endocrine-Related Cancer. 2025. doi:10.1530/erc-25-0089

BibTeX
@article{Yoo2025,
  author = {Yoo, Jungmin and Kim, Mijin and Kim, Hee Kyung and Shin, Dong Yeob and Jeon, Min Ji and Kim, Bo Hyun and Kang, Ho-Cheol and Lee, Jaekyung and Lim, Dong-Jun and Kim, Won Gu},
  title = {Next-generation sequencing of targetable gene fusions in radioiodine-refractory thyroid cancer: a multicenter study},
  journal = {Endocrine-Related Cancer},
  year = {2025},
  doi = {10.1530/erc-25-0089}
}
Kostenlos starten →